Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR
- PMID: 8557364
- PMCID: PMC173768
- DOI: 10.1128/iai.64.1.355-357.1996
Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR
Abstract
This study addresses a mechanism for inducing systemic immunity to Shiga-like toxins by oral administration of a Shiga-like toxin I B-subunit-expressing Vibrio cholerae vaccine strain [CVD 103-HgR(pDA60)]. Two sets of three rabbits were given either CVD 103-HgR or CVD 103-HgR(pDA60) orally. All rabbits immunized with CVD 103-HgR(pDA60) developed neutralizing serum antibodies to Shiga-like toxin I. None of the controls developed such antibodies.
Similar articles
-
A review of the current status of enteric vaccines.P N G Med J. 1995 Dec;38(4):325-31. P N G Med J. 1995. PMID: 9522876 Review.
-
Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.Infect Immun. 1999 Dec;67(12):6341-5. doi: 10.1128/IAI.67.12.6341-6345.1999. Infect Immun. 1999. PMID: 10569747 Free PMC article. Clinical Trial.
-
Protection against Shiga toxin-producing Escherichia coli infection by transcutaneous immunization with Shiga toxin subunit B.Clin Vaccine Immunol. 2008 Feb;15(2):359-66. doi: 10.1128/CVI.00399-07. Epub 2007 Nov 14. Clin Vaccine Immunol. 2008. PMID: 18003816 Free PMC article.
-
Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.FEMS Immunol Med Microbiol. 2009 Jul;56(2):179-84. doi: 10.1111/j.1574-695X.2009.00563.x. Epub 2009 May 5. FEMS Immunol Med Microbiol. 2009. PMID: 19453752
-
PaxVax CVD 103-HgR single-dose live oral cholera vaccine.Expert Rev Vaccines. 2017 Mar;16(3):197-213. doi: 10.1080/14760584.2017.1291348. Expert Rev Vaccines. 2017. PMID: 28165831 Review.
Cited by
-
Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections.Clin Microbiol Rev. 1998 Jul;11(3):450-79. doi: 10.1128/CMR.11.3.450. Clin Microbiol Rev. 1998. PMID: 9665978 Free PMC article. Review.
-
Live attenuated Shigella dysenteriae type 1 vaccine strains overexpressing shiga toxin B subunit.Infect Immun. 2011 Dec;79(12):4912-22. doi: 10.1128/IAI.05814-11. Epub 2011 Oct 3. Infect Immun. 2011. PMID: 21969003 Free PMC article.
-
Salmonella enterica serovar Typhimurium vaccine strains expressing a nontoxic Shiga-like toxin 2 derivative induce partial protective immunity to the toxin expressed by enterohemorrhagic Escherichia coli.Clin Vaccine Immunol. 2010 Apr;17(4):529-36. doi: 10.1128/CVI.00495-09. Epub 2010 Feb 10. Clin Vaccine Immunol. 2010. PMID: 20147499 Free PMC article.
-
Oral immunization with attenuated vaccine strains of Vibrio cholerae expressing a dodecapeptide repeat of the serine-rich Entamoeba histolytica protein fused to the cholera toxin B subunit induces systemic and mucosal antiamebic and anti-V. cholerae antibody responses in mice.Infect Immun. 1997 Aug;65(8):3118-25. doi: 10.1128/iai.65.8.3118-3125.1997. Infect Immun. 1997. PMID: 9234763 Free PMC article.
-
Treatment Strategies for Infections With Shiga Toxin-Producing Escherichia coli.Front Cell Infect Microbiol. 2020 May 6;10:169. doi: 10.3389/fcimb.2020.00169. eCollection 2020. Front Cell Infect Microbiol. 2020. PMID: 32435624 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical